Democratizing Biologics With Lumen Bioscience's Brian Finrow, J.D. & Craig Behnke, Ph.D.
Source: Bioprocess Online
![mattpillar-aboutus mattpillar-aboutus](https://vertassets.blob.core.windows.net/image/478396d3/478396d3-bafe-41dc-8c70-890fd8394bca/81_54-mattpillar_aboutus.png)
By Matthew Pillar, Editor, Bioprocess Online
![20_12_BPO_BusBiotech_Social_ep73 20_12_BPO_BusBiotech_Social_ep73](https://vertassets.blob.core.windows.net/image/51c482eb/51c482eb-5ec8-4f4c-8e26-0fc4eb5d79f3/375_250-20_12_bpo_busbiotech_social_ep73.png)
Making powerful and curative biologic therapies accessible to patients from all walks of life, and all corners of the globe, requires radically innovative thinking. On this episode of the Business of Biotech, Lumen Bioscience's Co-Founder and CEO Brian Finrow, J.D. and EVP of Production/Development Craig Behnke, Ph.D. discuss a novel approach: developing therapeutic proteins from readily-available food algae spirulina. It's driving a diverse pipeline of candidates into the clinic, for indications reaching from the gut to the heart and lungs.
access the Podcast!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.
Subscribe to Drug Discovery Online
X
Subscribe to Drug Discovery Online
Bioprocess Online
This website uses cookies to ensure you get the best experience on our website. Learn more